NCT05724433 VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization
| NCT ID | NCT05724433 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Population Health Research Institute |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 891 participants |
| Start Date | 2023-01-23 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 891 participants in total. It began in 2023-01-23 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.
Eligibility Criteria
Inclusion Criteria: Adult patients ≥ 18 years old who: 1. Are being discharged after hospitalization or urgent visit for HF as 1. a primary diagnosis or 2. significant complication (prolonging length of stay) of another diagnosis OR Have been referred for an initial consult at a cardiology clinic within 1 week of hospitalization or urgent visit for HF as a primary or secondary diagnosis, as described above. 2. Have left ventricular ejection fraction (LVEF) \< 50% within the preceding 3 months. 3. Have NT-proBNP of \> 900 pg/ml during hospital admission or within 7 days after discharge from the ED 4. Have a mailing address for patient or caregiver 5. Provide verbal consent Exclusion Criteria: 1. Died or left hospital before medically advised hospital discharge 2. Unable to self-assess or communicate symptoms (e.g. clinically evident dementia) 3. Unable to engage with digital health technology or follow up 4. Severe valve disease 5. Recipient of or on waiting list for LVAD or cardiac transplant 6. Complex congenital heart disease, hypertrophic obstructive cardiomyopathy, or amyloid cardiomyopathy 7. Severe lung disease with symptoms on minimal exertion, forced expiratory volume during 1 second (FEV1) \< 1 litre, severe pulmonary hypertension with RVSP \> 60 mm Hg, or on home oxygen 8. Severe kidney disease (persistent eGFR \< 30 mL/min/1.73m2) 9. Active malignancy 10. Receiving palliative care or expected life expectancy \< 6 months
Contact & Investigator
Harriette Van Spall, MD
PRINCIPAL INVESTIGATOR
McMaster University
Frequently Asked Questions
Who can join the NCT05724433 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05724433 currently recruiting?
Yes, NCT05724433 is actively recruiting participants. Contact the research team at Harriette.VanSpall@phri.ca for enrollment information.
Where is the NCT05724433 trial being conducted?
This trial is being conducted at Hamilton, Canada, Hamilton, Canada, Hamilton, Canada, Thunder Bay, Canada and 5 additional locations.
Who is sponsoring the NCT05724433 clinical trial?
NCT05724433 is sponsored by Population Health Research Institute. The principal investigator is Harriette Van Spall, MD at McMaster University. The trial plans to enroll 891 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.